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Recent studies have suggested that plasma-derived proteins may bepotential biomarkers relevant for graft-versus-host disease and/ornon-relapse mortality occurring after allogeneic blood or marrow
transplantation.  However, none of these putative biomarkers have been
assessed in patients treated either with human leukocyte antigen-hap-
loidentical blood or marrow transplantation or with post-transplantation
cyclophosphamide, which has been repeatedly associated with low rates
of severe acute graft-versus-host disease, chronic graft-versus-host disease,
and non-relapse mortality. We explored whether seven of these plasma-
derived proteins, as measured by enzyme-linked immunosorbent assays,
were predictive of clinical outcomes in post-transplantation cyclophos-
phamide-treated patients using plasma samples collected at serial pre-
determined timepoints from patients treated on prospective clinical stud-
ies of human leukocyte antigen-haploidentical (n=58; clinicaltrials.gov
Identifier: 00796562) or human leukocyte antigen-matched-related or 
-unrelated (n=100; clinicaltrials.gov Identifiers: 00134017 and 00809276) 
T-cell-replete bone marrow transplantation.  Day 30 levels of interleukin-
2 receptor α, tumor necrosis factor receptor 1, serum STimulation-2
(IL1RL1 gene product), and regenerating islet-derived 3-α all had high
areas under the curve of 0.74-0.97 for predicting non-relapse mortality
occurrence by 3 months post-transplant in both the human leukocyte
antigen-matched and human leukocyte antigen-haploidentical cohorts. In
both cohorts, all four of these proteins were also predictive of subsequent
non-relapse mortality occurring by 6, 9, or 12 months post-transplant and
were significantly associated with non-relapse mortality in univariable
analyses.  Furthermore, day 30 elevations of interleukin-2 receptor αwere
associated with grade II-IV and III-IV acute graft-versus-host disease occur-
ring after day 30 in both cohorts. These data confirm that plasma-derived
proteins previously assessed in other transplantation platforms appear to
retain prognostic and predictive utility in patients treated with post-trans-
plantation cyclophosphamide.  
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ABSTRACT
Introduction
High-dose, post-transplantation cyclophosphamide
(PTCy) provides effective graft-versus-host disease
(GvHD) prophylaxis after allogeneic blood or marrow
transplantation (alloBMT).1 This approach has facilitated
the safe performance of T-cell-replete human leukocyte
antigen (HLA)-haploidentical alloBMT1-3 and can function
as single-agent GvHD prophylaxis after myeloablative
conditioning and HLA-matched bone marrow
allografting.1,4-6 Despite these clinical successes with low
rates of severe acute GvHD, chronic GvHD, and non-
relapse mortality (NRM), biomarkers prognostic for
GvHD or predictive for NRM occurring despite the use of
PTCy have not been explored.  Such biomarkers could
potentially help guide treatment decisions and direct more
intensive clinical surveillance of patients at high-risk for
poor outcomes. Furthermore, they may provide biologic
insight into immunologic pathways that could be targeted
to prevent adverse clinical events.
A number of candidate plasma-derived biomarkers have
been examined in other alloBMT platforms,7-23 and several
have repeatedly been found to be associated with clinical
outcomes.  In the study herein, we focused on seven par-
ticularly promising proteins.  These proteins are all biolog-
ically plausible molecules either related directly to the
inflammatory response thought to mediate GvHD (inter-
leukin [IL]-2 receptor α [IL-2Rα],24 IL-6,25 tumor necrosis
factor receptor 1 [TNFR-1],26 serum STimulation-2 (IL1RL1
gene product) [ST2],27,28 and chemokine [C-X-C motif] lig-
and 9 [CXCL9]29), or are released from tissue directly dam-
aged by GvHD (lower gastrointestinal tract [regenerating
islet-derived 3-α, REG3α]30-32 and skin [elafin]33). When
measured at the start of clinical acute GvHD, elevated
plasma levels of IL-2Rα, IL-6, TNFR-1, ST2, REG3α, and
elafin have been associated with the presence and predict-
ed severity of acute GvHD, response to immunosuppres-
sive therapy, and/or risk for NRM.7-9,12-17,21 Plasma levels of
CXCL9, IL-2Rα, and elafin measured at the time of onset
of chronic GvHD have been associated with chronic
GvHD diagnosis; CXCL9 had the highest predictive accu-
racy and was also associated with chronic GvHD severi-
ty.18 
A few studies have examined the utility of biomarker
measurements at pre-determined timepoints. When meas-
ured at day 7 after myeloablative alloBMT, elevated plas-
ma levels of TNFR-1 were associated with an increased
incidence of NRM and an increased incidence and severity
of acute GvHD.10 Elevated plasma levels of ST2 at days 14
or 21 after myeloablative alloBMT or day 14 after
reduced-intensity conditioning alloBMT were associated
with an increased risk of NRM.17 In patients receiving dou-
ble umbilical cord blood transplantation (dUCBT), elevat-
ed day 28 plasma levels of ST2 were associated with an
increased incidence of NRM and grade II-IV and III-IV
acute GvHD occurring after that timepoint; elevated day
28 plasma levels of TNFR-1 and REG3α, while not associ-
ated with acute GvHD, were associated with an increased
risk of NRM.20 Finally, in patients treated with myeloab-
lative HLA-matched-related alloBMT using either
tacrolimus/sirolimus or tacrolimus/methotrexate for
GvHD prophylaxis, elevated day 28 plasma levels of ST2,
REG3α, and IL-6 were all associated with an increased risk
of NRM, but were not associated with GvHD risk.23
With the increasing use of PTCy worldwide and the
clinical observations (e.g., low incidence of chronic
GvHD) suggesting that PTCy may modulate GvHD risk in
a dissimilar way to other T-cell-replete alloBMT approach-
es,1 we explored whether these seven promising candidate
biomarkers had utility in prognosticating clinical out-
comes for PTCy-treated patients.  We assessed plasma lev-
els using blood previously collected at serial pre-deter-
mined timepoints from 158 patients treated on one of
three prospective clinical studies of PTCy as GvHD pro-
phylaxis after myeloablative alloBMT using either HLA-
matched or HLA-haploidentical donors.4,6,34 We hypothe-
sized that plasma elevations in these proteins might be
associated with negative clinical outcomes, particularly
NRM, for PTCy-treated patients.
Methods
Study design
This study was designed to assess whether plasma-derived pro-
teins, measured at specific post-transplant timepoints, are predic-
tive of NRM occurrence or prognostic for the development of
acute or chronic GvHD after alloBMT using PTCy as GvHD pro-
phylaxis.  The sample was based on the number of available plas-
ma specimens previously collected at pre-determined timepoints
from patients treated on one of three prospective clinical studies
(clinicaltrials.gov Identifiers: 00134017,  00809276, and 00796562)
(Online Supplementary Figure S1).  Due to differences in the donor
sources and adjunct GvHD prophylaxis, patients receiving HLA-
matched versus HLA-haploidentical alloBMT were analyzed in
separate cohorts for all analyses.
Patients and samples
All three studies exclusively employed myeloablative condition-
ing and T-cell-replete bone marrow allografts. Two of the clinical
trials, (clinicaltrials.gov Identifiers: 00134017 and 00809276), were
both prospective studies of HLA-matched-related or -unrelated
donor alloBMT using PTCy as single-agent GvHD prophylaxis for
adult patients with advanced hematologic malignancies.4,6 One of
these, (clinicaltrials.gov Identifier: 00134017), was a single-institu-
tional study using busulfan/cyclophosphamide conditioning
(n=122);4 although this study spanned 2004-2009, plasma was
only cryopreserved for a group of 35 patients transplanted in 2007
and 2008. The other, (clinicaltrials.gov Identifier: 00809276), was a
multi-institutional study using busulfan/fludarabine conditioning
(n=92);6 as part of that protocol, plasma samples from all 80
patients treated at two of the three participating centers (Johns
Hopkins Hospital and Fred Hutchinson Cancer Research Center)
were collected. The third  trial, (clinicaltrials.gov Identifier:
00796562), was a single-institutional prospective study of busul-
fan/cyclophosphamide conditioning, HLA-haploidentical donor
alloBMT, and GvHD prophylaxis using PTCy, mycophenolate
mofetil (MMF), and tacrolimus for adult or pediatric patients with
advanced hematologic malignancies (n=95).34 Plasma samples
were collected for 92 patients.  As this latter trial enrolled patients
with chemorefractory hematologic malignancies and the study did
not mandate specimen collection once a patient relapsed, patients
on this trial that relapsed less than 6 months post-transplant (n=23)
were not included in this analysis.
Blood was collected only at pre-determined timepoints.
Patients who experienced graft failure (n=10), suffered NRM prior
to day 30 (n=4), or survived to day 30 and had sustained engraft-
ment but did not have a day 30 plasma sample collected (n=12)
were excluded (Online Supplementary Figure S1). Both studies of
HLA-matched alloBMT (clinicaltrials.gov Identifiers: 00134017 and
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00809276) were combined together as a single cohort for analysis
as these patients were identically treated except for the type of
myeloablative conditioning (cyclophosphamide versus fludarabine
in addition to busulfan). Ultimately, 100 patients receiving HLA-
matched alloBMT and 58 patients receiving HLA-haploidentical
alloBMT were included in this study (Table 1; Online
Supplementary Figure S1).  Plasma samples from 33 healthy donors
of bone marrow for patients treated on the two latter mentioned
trials were also included in these analyses. All patients and healthy
donors provided written informed consent on institutional review
board-approved protocols prior to specimen collection.
Proteomic analysis
Enzyme-linked immunosorbent assays (ELISAs) for IL-2Rα, 
IL-6, TNFR-1, ST2, elafin, REG3α, and CXCL9 were performed in
batches on cryopreserved plasma.12-14,16-18,20 All of these biomark-
ers were measured using sequential ELISA as previously report-
ed.35 These methods are described in detail in the Online
Supplementary Methods.  
Statistical analysis
Statistical comparisons between donors and recipients regard-
ing biomarker levels at various timepoints were based on the non-
parametric Mann-Whitney test. In order to account for multiple
hypothesis testing due to the multiple timepoints, we applied the
Bonferroni type I error adjustment.  All other outcomes were ana-
lyzed under the competing risks framework.36 Definitions of end-
points and competing risks are defined in the Online Supplementary
Methods. To explicitly quantify the predictive accuracy of each bio-
marker at 30 days for the different outcomes of the study, and to
account for both the time-dependency of the outcomes and the
competing risks, time-dependent receiver operating characteristic
(ROC) curves for competing endpoints were computed.37
Predictive accuracy was estimated based on the area under the
ROC curve at 3, 6, 9, and 12 months. To assess the association of
each biomarker with outcomes, the linear effect of the biomarker
(treated as a continuous variable), either alone or adjusted for the
potential confounders of recipient age and recipient
cytomegalovirus serostatus, on the cumulative incidence was esti-
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Table 1. Patient, donor, and transplantation characteristics.
Characteristics                                                              HLA-Matched                 HLA-Haploidentical                                 All Patients
                                                                                          (n=100)                               (n=58)                                             (n=158)
Donor, n (%)
Related                                                                                             42 (42%)                                  58 (100%)                                                  100 (63%)
Unrelated                                                                                        58 (58%)                                        N/A                                                         58 (37%)
Conditioning
Bu/Cy                                                                                                 30 (30%)                                  58 (100%)                                                   88 (56%)
Bu/Flu                                                                                               70 (70%)                                     0 (0%)                                                      70 (44%)
GvHD prophylaxis                                                                          PTCy alone                          PTCy, MMF, tacro                                                     
Age, y, median (range)                                                                  51 (22-65)                                  42 (2-64)                                                    49 (2-65)
Sex, n (%) female                                                                            57 (57%)                                   27 (47%)                                                    84 (53%)
Diagnosis, n (%)
AML/MDS/CMML                                                                           73 (73%)                                   33 (57%)                                                   106 (67%)
ALL                                                                                                    16 (16%)                                    8 (14%)                                                     24 (15%)
NHL/CLL                                                                                            3 (3%)                                      9 (16%)                                                      12 (8%)
Hodgkin lymphoma                                                                          0 (0%)                                       4 (7%)                                                        4 (3%)
CML                                                                                                    6 (6%)                                       4 (7%)                                                       10 (6%)
Multiple myeloma                                                                            2 (2%)                                       0 (0%)                                                        2 (1%)
Remission status at alloBMT, n (%)
CR without MRD                                                                            52 (52%)                                   31 (53%)                                                    83 (53%)
CR with MRD                                                                                  23 (23%)                                    9 (16%)                                                     32 (20%)
Not in CR                                                                                         25 (25%)                                   18 (31%)                                                    43 (27%)
HCT-CI score, median (range)                                                       2 (0-8)                                       1 (0-5)                                                        2 (0-8)
Donor age, y, median (range)                                                     41 (17-67)                                 36 (11-69)                                                  40 (11-69)
Donor sex, n (%) female                                                               56 (56%)                                   34 (59%)                                                    90 (57%)
Female donor into male recipient, n (%)                                 23 (23%)                                   18 (31%)                                                    41 (26%)
CMV serostatus
D-/R-                                                                                                 31 (31%)                                   28 (48%)                                                    59 (37%)
D+/R-                                                                                                16 (16%)                                   10 (18%)                                                    26 (16%)
D-/R+                                                                                                30 (30%)                                    9 (16%)                                                     39 (25%)
D+/R+                                                                                              22 (22%)                                   11 (19%)                                                    33 (21%)
Dunk/R+                                                                                                1 (1%)                                       0 (0%)                                                        1 (1%)
Allograft cell counts, # (range)/kg recipient weight                        
Total nucleated cells, x 108                                                      4.09 (1.3-8.82)                         4.84 (2.63-11.2)                                          4.31 (1.3-11.2)
CD34+ cells, x 106                                                                       3.72 (1.0-9.87)                         4.16 (1.68-9.73)                                          3.82 (1.0-9.87)
CD3+ cells, x 107                                                                          3.8 (0.6-7.75)                         4.67 (1.09-11.07)                                        4.11 (0.6-11.07)
HLA: human leukocyte antigen; Bu: busulfan; Cy: cyclophosphamide; Flu: fludarabine; GvHD: graft-versus-host disease; tacro: tacrolimus; PTCy: post-transplantation cyclophos-
phamide; MMF: mycophenolate mofetil; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; ALL: acute lymphoblastic
leukemia; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; CML: chronic myelogenous leukemia; alloBMT: allogeneic bone marrow transplantation; CR: mor-
phologic complete remission; MRD: minimal residual disease; HCT-CI, hematopoietic cell transplantation-comorbidity index; CMV: cytomegalovirus; D: donor; R: recipient; unk:
unknown. 
mated under the semiparametric proportional subdistribution haz-
ards model (Fine-Gray model).38 Additionally, day 30 biomarker
values were dichotomized (higher than or equal to median value
vs. lower than median value), and cumulative incidence functions,
estimated using the nonparametric Aalen-Johansen estimator,39
were plotted.  Statistical comparisons between the cumulative
incidence curves for the outcome by the biomarker level cate-
gories were undertaken using Gray’s nonparametric test.40 All
analyses were performed separately for the HLA-matched and
HLA-haploidentical cohorts.
Results
Plasma-derived putative proteomic biomarkers are 
elevated post-transplant
Plasma levels of all seven tested proteins were signifi-
cantly elevated in patients post-transplant compared with
plasma levels of their healthy bone marrow donors (Figure
1). Levels of IL-2Rα, TNFR-1, ST2, and IL-6 were highest
at 30 days post-transplant, declined at subsequent post-
transplant measurements, and had similar temporal kinet-
ics between the HLA-matched and HLA-haploidentical
cohorts (Figure 1). Levels of the other three proteins were
relatively stable during the first post-transplant year, but
differed between the two cohorts: REG3α and CXCL9
levels were higher in the HLA-matched cohort, while
elafin levels were higher in the HLA-haploidentical cohort
(Figure 1). The differences in REG3α levels between the
two cohorts may be related to the much higher incidence
of gastrointestinal acute GvHD in the HLA-matched
cohort (39% versus 12%) (Online Supplementary Table S1).
The difference in elafin levels between cohorts was not
directly attributable to varying GvHD rates, as the inci-
dence of cutaneous acute GvHD was higher in the HLA-
matched cohort (Online Supplementary Table S1).
Day 30 IL-2Rα, TNFR-1, ST2, and REG3α are 
consistently predictive of the occurrence of 
non-relapse mortality
Using the first post-transplant timepoint (day 30) sam-
ples, levels of each of the seven proteins were tested for
associations with subsequent occurrence of NRM. First,
time-dependent ROC curves, which relate a biomarker’s
sensitivity and specificity, were generated to assess the
overall accuracy (area under the ROC curve) of each bio-
marker for predicting NRM. Separate ROC curves were
generated for each cohort (HLA-matched and HLA-hap-
loidentical) (Figure 2). In both cohorts, IL-2Rα, TNFR-1,
ST2, and REG3α all had high area under the curve (AUC)
values of 0.74-0.97, consistent with high degrees of predic-
tive accuracy for NRM occurrence by 3 months post-trans-
plant (Figure 2). In the HLA-haploidentical cohort, elafin
and IL-6 also had high AUC values of 0.72-0.83 (Figure 2).
Biomarkers for post-transplant cyclophosphamide
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Table 2. Univariable associations of day 30 biomarker levels with acute GvHD and non-relapse mortality.
Grade II-IV Grade III-IV Non-Relapse Mortality
Acute GvHD Acute GvHD
Biomarker SHR (95% CI) P SHR (95% CI) P SHR (95% CI) P
IL-2Rα (per 500 units)
HLA-matched 1.27 (1.06-1.53) 0.01 1.47 (1.18-1.83) 0.001 1.55 (1.17-2.05) 0.002
HLA-haploidentical 1.66 (1.04-2.64) 0.03 1.61 (1.08-2.41) 0.021 1.88 (1.28-2.76) 0.001
TNFR-1 (per 1000 units)
HLA-matched 1.04 (0.96-1.13) 0.33 1.09 (1.00-1.19) 0.05 1.22 (1.07-1.38) 0.002
HLA-haploidentical 1.00 (0.91-1.10) 0.99 1.01 (0.88-1.16) 0.93 1.28 (1.20-1.36) <0.001
ST2 (per 20 units)
HLA-matched 1.04 (0.95-1.15) 0.39 1.06 (0.88-1.27) 0.56 1.12 (1.02-1.23) 0.013
HLA-haploidentical 1.10 (0.92-1.33) 0.30 1.10 (0.89-1.37) 0.36 1.41 (1.26-1.56) <0.001
REG3α  (per 20 units)
HLA-matched 1.00 (0.98-1.02) 0.60 1.01 (0.99-1.03) 0.24 1.05 (1.04-1.07) <0.001
HLA-haploidentical 0.99 (0.98-1.00) 0.11 0.99 (0.97-1.01) 0.17 1.01 (1.01-1.01) <0.001
Elafin (per 1000 units)
HLA-matched 1.02 (0.98-1.07) 0.32 1.00 (0.94-1.06) 0.98 1.00 (0.93-1.06) 0.88
HLA-haploidentical 1.06 (0.99-1.13) 0.09 1.03 (0.98-1.08) 0.31 1.11 (1.06-1.17) <0.001
IL-6 (per 10 units)
HLA-matched 1.00 (0.99-1.01) 0.98 1.00 (0.99-1.02) 0.69 1.00 (0.98-1.02) 0.91
HLA-haploidentical 0.97 (0.83-1.13) 0.68 0.12 (0.02-0.80) 0.03 1.03 (1.02-1.04) <0.001
CXCL9 (per 5 units)
HLA-matched 1.02 (0.98-1.06) 0.24 1.03 (0.99-1.07) 0.17 1.03 (0.98-1.08) 0.25
HLA-haploidentical 1.50 (0.92-2.44) 0.10 2.70 (1.80-4.04) <0.001 1.23 (0.73-2.09) 0.44
For grade II-IV acute GvHD, the numbers of events and competing risks were 31 and 23 for the HLA-matched cohort and 6 and 19 for the HLA-haploidentical cohort, respectively.
For grade III-IV acute GvHD, the numbers of events and competing risks were 16 and 39 for the HLA-matched cohort and 2 and 23 for the HLA-haploidentical cohort, respectively.
For non-relapse mortality, the numbers of events and competing risks were 14 and 37 for the HLA-matched cohort and 10 and 12 for the HLA-haploidentical cohort, respectively.
Biomarkers for these analyses were assessed as continuous variables.  The SHR listed for each biomarker/outcome is the risk per given number of biomarker units shown. GvHD:
graft-versus-host disease; IL-2Rα: interleukin-2 receptor α; TNFR-1: tumor necrosis factor receptor-1; ST2: serum STimulation-2, IL1RL1 gene product; REG3α: regenerating islet-
derived 3-α; IL-6: interleukin-6; CXCL9: chemokine [C-X-C motif] ligand 9; HLA: human leukocyte antigen; SHR: subdistribution hazard ratio; CI: confidence interval. 
In both cohorts, the AUC values remained high for each of
these biomarkers when assessing NRM occurring by 6, 9,
or 12 months post-transplant, suggesting that early eleva-
tions in these biomarkers may be predictive of both short-
er and longer term NRM risk.
In univariable analyses for association with NRM, high
day 30 levels of IL-2Rα, TNFR-1, ST2, and REG3α were
significantly associated with greater cumulative incidence
of NRM within each cohort (Table 2). High elafin and IL-
6 levels were also associated with NRM in the HLA-hap-
loidentical cohort only (Table 2), while CXCL9 was not
associated with NRM in either cohort. As prior analyses
had shown significant associations of recipient age and
recipient cytomegalovirus serostatus with NRM,5 bio-
marker analyses were subsequently adjusted for these two
factors and showed similar results as the unadjusted uni-
variable analyses (Online Supplementary Table S2).
To provide results comparable with one of the most
analogous alloBMT biomarker studies,20 the association of
each protein with NRM was also assessed for each cohort
by dichotomizing each biomarker at the median and non-
parametrically estimating the cumulative incidence func-
tions of each outcome (Online Supplementary Tables S3 and
S4). Of note, in all univariable analyses, there were no sig-
nificant associations between day 30 levels for any of the
seven proteins and subsequent relapse of malignant dis-
ease. 
Day 30 IL-2Rα levels are consistently prognostic for
the occurrence of acute GvHD
The timing of sample collection was not ideal for assess-
ing the potential association of these biomarkers with
acute GvHD as 31 patients (19.6%) had onset of grade II-
IV acute GvHD prior to day 30. Despite this limitation,
and in order to better understand the associations with
subsequent NRM, we did assess whether these biomark-
ers were prognostic for acute GvHD occurring after day
30.  Importantly, the NRM for patients with grade II-IV
acute GvHD onset prior to day 30 was not higher than the
NRM of patients who developed grade II-IV acute GvHD
after day 30 (time-dependent proportional cause-specific
hazard ratio (HR), grade II-IV acute GvHD developing
after day 30 compared with before day 30, HR 1.14 (95%
confidence interval  (CI) 0.41-3.16); P=0.81). Furthermore,
there was no evidence that the risk of developing grade III-
IV acute GvHD was different in those who developed
grade II-IV acute GvHD after day 30 compared with
before day 30 based on Fisher’s exact test (P=0.68) or the
Cox proportional cause-specific hazards model (HR 1.3
(95% CI 0.5-3.35), P=0.59).
In testing associations with grade II-IV acute GvHD
using the day 30 protein levels, ROC curves showed high
AUC values of >0.7 in both cohorts for IL-2Rα, TNFR-1,
and CXCL9, consistent with high predictive accuracy for
grade II-IV acute GvHD occurring after day 30 (Online
Supplementary Figures S2 and S3). In the HLA-haploidenti-
cal cohort, ST2 and REG3α also had high AUC values of
approximately 0.9 for grade II-IV acute GvHD, although
the number of events (n=6) was low (Online Supplementary
Figure S3). In testing associations with grade III-IV acute
GvHD development after day 30, day 30 IL-2Rα, CXCL9,
and REG3α levels all had high AUC values (>0.73 for the
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Figure 1. Dynamics of biomarker levels over time. Plasma biomarker levels are shown for healthy bone marrow donors (n=33) and for patients at pre-transplant and
serial pre-defined (1, 2, 6, and 12 months) post-transplant timepoints. The number of samples for the HLA-haploidentical cohort is as follows:  pre-transplant n=53,
1 month n=58, 2 months n=54, 6 months n=41, 12 months n=18.  The number of samples for the HLA-matched cohort is as follows: pre-transplant n=93, 1 month
n=100, 2 months n=90, 6 months n=33, 12 months n=36. Samples for the HLA-matched and HLA-haploidentical cohorts were drawn at the same timepoints, but
are shown slightly staggered for the sake of clarity.  Asterisks show statistically significant differences for each cohort compared with donor levels. IL-2Rα: interleukin-
2 receptor α; TNFR-1: tumor necrosis factor receptor 1; ST2: serum STimulation-2, IL1RL1 gene product; CXCL9: chemokine [C-X-C motif] ligand 9; REG3α: regener-
ating islet-derived 3-α; IL-6: interleukin-6; BMT: allogeneic bone marrow transplantation; HLA: human leukocyte antigen; CI: confidence interval. 
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Figure 2. Time-dependent ROC curves for NRM separated by donor type. Using day 30 biomarker levels, ROC curves for predicting subsequent NRM occurrence by
3, 6, 9, or 12 months post-transplant are shown separately for the (A) HLA-matched and (B) HLA-haploidentical cohorts. The analysis was performed using a com-
peting risks framework with relapse as a competing risk for NRM. IL-2Rα: interleukin-2 receptor α; TNFR-1: tumor necrosis factor receptor 1; ST2: serum STimulation-
2, IL1RL1 gene product; CXCL9: chemokine [C-X-C motif] ligand 9; REG3α: regenerating islet-derived 3-α; IL-6: interleukin-6; AUC: area under the curve.
A
B
HLA-matched cohort and >0.9 for the HLA-haploidentical
cohort) (Online Supplementary Figures S4 and S5). Within
the HLA-haploidentical cohort, day 30 TNFR-1, ST2, and
elafin levels also had high AUC values (>0.8) for grade III-
IV acute GvHD, while IL-6 had a low AUC value (0.18),
although again the event number was quite low (n=2). In
univariable analyses, high day 30 IL-2Rα levels were con-
sistently associated with a greater cumulative incidence of
both grade II-IV and grade III-IV acute GvHD (Table 2 and
Online Supplementary Table S2; Online Supplementary Figures
S2-S5).
Six-month plasma protein levels were used to evaluate
for an association with chronic GvHD development.
However, only 71 of the 125 patients (56.8%) that were
chronic GvHD-free and still at risk for chronic GvHD at 6
months had 6-month samples collected. Univariable
analyses with chronic GvHD development did not show
any statistically significant associations, although CXCL9
trended towards significance in the HLA-haploidentical
cohort (HLA-haploidentical cohort, HR 1.49 (95% CI 0.93-
2.40), P=0.096; HLA-matched cohort, HR 1.12 (95% CI
0.95-1.32), P=0.17).
Discussion
In the study herein, we explored whether putative pro-
teomic biomarkers, previously assessed using other trans-
plantation platforms, were applicable to PTCy-treated
patients. Among its novel features, our study is the first to
examine the relevance of promising biomarkers in PTCy-
treated patients or patients receiving HLA-haploidentical
alloBMT. All patients were uniformly treated with mye-
loablative conditioning, bone marrow allografts, and
PTCy for GvHD prophylaxis, and we found effects that
appear to be conserved across different donor sources.
Furthermore, we have used novel statistical methods to
address our scientific aims. These include the Fine-Gray
model to directly estimate the effect of an independent
variable on the cumulative incidence function of the out-
come of interest in the presence of competing risks and
also time-dependent ROC curve methodology for com-
peting risks to directly quantify the predictive accuracy of
each biomarker.
We found that, despite low rates of NRM and severe
GvHD in PTCy-treated patients, elevated levels of several
of these plasma proteins remained prognostic for adverse
outcomes. Consistently in both cohorts, elevations in 
IL-2Rα, TNFR-1, ST2, and REG3α at 30 days post-trans-
plant each were significantly associated with a greater
cumulative incidence of NRM. Furthermore, in both
cohorts, elevations in IL-2Rα at 30 days post-transplant
were associated with subsequent grade II-IV and III-IV
acute GvHD occurrence.
Prior studies of putative proteomic biomarkers in other
transplantation platforms, using plasma measurements at
pre-determined timepoints during the first post-transplant
month, have shown associations between levels of TNFR-
1, ST2, and REG3α and subsequent occurrence of NRM
and/or acute GvHD.10,17,20,23 Most consistent with our
results, a recent large study of patients treated with HLA-
matched-related alloBMT showed that elevated day 28
ST2 and REG3α levels were associated with greater risk
for NRM, but did not have a significant relationship with
acute or chronic GvHD.23 Also compatible with our
results, a study of patients undergoing dUCBT found that
elevations in TNFR-1, ST2, and REG3α at day 28 post-
transplant were associated with NRM at 180 days.20 In
contrast to their results, but consistent with the HLA-
matched-related alloBMT study, we did not find a statisti-
cally significant association between ST2 levels and acute
GvHD.  Furthermore, in the dUCBT study, elevations
above the median in IL-2Rα were not associated with
GvHD or NRM, whereas our study showed strong associ-
ations of IL-2Rα with grade II-IV acute GvHD, grade III-IV
acute GvHD, and NRM. The strong relationship we found
between day 30 IL-2Rα levels and acute GvHD was con-
sistent with another study that demonstrated a peak in IL-
2Rα levels at 14 days post-transplant in patients who
would subsequently develop acute GvHD.7 Moreover, our
results are consistent with other studies which have
shown associations between IL-2Rα levels measured at
the start of acute GvHD and subsequent NRM.12,16 In con-
trast with prior studies that showed that day 14 IL-6 levels
were prognostic of subsequent grade III-IV acute GvHD
occurrence or that day 28 IL-6 levels were prognostic of
NRM,21,23 we did not find a consistent relationship
between IL-6 and outcomes between our two cohorts.
Our study has several limitations. Importantly, we do
not have an independent verification cohort as we uti-
lized all plasma samples available from three prospective
studies of PTCy. Furthermore, cross-validation was not
performed to evaluate the out-of-sample predictive abili-
ty of our model. This is because the goal of the present
study was neither to propose a specific model for the
alloBMT-related outcomes nor to provide a specific clas-
sification/prediction rule. Our goal was to evaluate the
predictive potential of a set of biomarkers, and therefore
we quantified this using time-dependent ROC curves for
competing risks. Even so, we found consistent results
between the two cohorts in terms of four predictors of
NRM and one predictor of acute GvHD, suggesting that
our results may have some external validity.  Differences
in plasma protein levels and associations for three of the
tested biomarkers (CXCL9, REG3α, and elafin) between
the HLA-matched and HLA-haploidentical cohorts could
reflect differences in the biology of donor HLA disparity,
but more likely reflect the differences in the immunosup-
pressants used (the former used PTCy alone, whereas the
latter also incorporated MMF and tacrolimus), as demon-
strated in a recent publication regarding REG3α,23 in addi-
tion to the differing incidences of acute GvHD (lower
grade II-IV and III-IV acute GvHD rates for the HLA-hap-
loidentical cohort) probably due to this adjunct immuno-
suppression therapy. Unfortunately, our limited number
of events for NRM and GvHD outcomes made it statisti-
cally infeasible to perform multivariable analyses to
attempt to thoroughly dissect the impact of other poten-
tial confounders. Another limitation of this study is that
we did not adjust for type I error inflation due to multiple
statistical testing in the univariable models. However, the
main purpose of this work was to estimate the predictive
accuracy for a set of biomarkers that had already been
reported to be associated with NRM and GvHD in previ-
ous reports using other transplantation platforms. The
evaluation of this predictive accuracy was not based on
hypothesis testing but on the calculation of ROC AUCs.
Furthermore, hypothesis tests that were conducted were
specified a priori and were confirmatory in nature rather
than exploratory.
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Lastly, our study is limited by the sample collection per-
formed. Our samples were collected at uniform pre-deter-
mined timepoints, but samples from patient-specific time-
points (e.g., at GvHD diagnosis or longitudinally in
response to GvHD treatment) were not collected.
Furthermore, the first post-transplant plasma samples
were taken at day 30; 20% of patients had experienced the
onset of grade II-IV acute GvHD prior to that timepoint
and had to be excluded from the acute GvHD analyses.
Thus, our results for acute GvHD are only relevant for
patients surviving to day 30 without yet developing acute
GvHD. The apparent lack of statistical association of some
of these proteins (e.g., ST2, REG3α, or elafin for acute
GvHD) with clinical outcomes in our patients could in part
be explained by these temporal and contextual differences
in sampling; had samples been collected earlier post-trans-
plant or at the time of diagnosis of acute GvHD, these pro-
teins may have had a more apparent prognostic import.
While the HLA-haploidentical cohort also suffered from
exclusion of patients who relapsed within 6 months post-
transplant, those patients would not have remained at risk
for NRM or GvHD in any case due to the occurrence of a
competing risk. Thus, the main findings of this manuscript
would likely remain unchanged even if samples had been
universally available for those patients.  Moreover, many
of the results in the HLA-haploidentical cohort were con-
firmed in the HLA-matched cohort, in which there was no
bias in sample availability.
Even though PTCy is broadly and highly effective in
preventing chronic GvHD in patients undergoing
alloBMT,1,2,4-6 our study has not revealed any factor that can
prognosticate which of our patients will still develop
chronic GvHD despite PTCy treatment.  It is possible that
the lack of any significant findings was due in part to the
low incidence of chronic GvHD in our patients and thus
low statistical power to detect true differences that may
exist; however, the number of chronic GvHD events
(n=24) was identical to the number of NRM events (n=24)
and more than the number of grade III-IV acute GvHD
events (n=18). Further insight may require a better under-
standing of the underlying biology of chronic GvHD,
which remains poorly defined.41 Immunologic parameters
could potentially be of interest given the recently demon-
strated role for regulatory T cells in GvHD prevention by
PTCy,42,43 but such studies would require a large number of
patients for adequate statistical power given the low inci-
dence of chronic GvHD development in PTCy-treated
patients.
Although not prognostic for chronic GvHD, elevations
in IL-2Rα, TNFR-1, ST2, and REG3α at day 30 post-trans-
plant were consistently predictive of NRM occurrence in
our patients. While IL-2Rα was also prognostic for acute
GvHD occurrence in both cohorts, the majority of our
patients did not die from GvHD-related causes (Online
Supplementary Table S5). This apparent disconnect
between predictors of GvHD and NRM was also seen in a
recent study of HLA-matched alloBMT in which day 28
plasma biomarker assessments were studied.23 Thus,
whether elevations in these proteins are specific for GvHD
is unclear. It is possible that GvHD and many cases of
NRM are both direct sequelae of a dysregulated immune
system, which is what many of these proteins are directly
measuring. Further dissection of what elevations in each
of these biomarkers mean, particularly in cases where
they are not correlated with each other, would require
complex prospective assessment of a host of clinical and
immunologic factors and would require a large number of
patients in addition to pre-clinical supporting studies.
Beyond the immediate risk for NRM, it is disconcerting
that day 30 elevations of these proteins are associated
with an increased risk for NRM in our patients, which
remains present for at least the first post-transplant year.
Given this apparent longer term risk, a fundamental out-
standing question is whether this risk is modifiable with
more intensive monitoring, immunosuppressive treat-
ment, or other novel interventions. Conversely, perhaps
low levels of these plasma proteins could justify less inten-
sive monitoring in such patients (i.e., risk-adapted thera-
py). If the risk is modifiable, what is the earliest post-
transplant timepoint at which this risk could be deter-
mined such that an intervention could be expeditiously
implemented? Prospective studies are required to further
clarify the role of biomarkers in facilitating personalized,
risk-adapted strategies for monitoring patients after
alloBMT. This may be particularly relevant as older and
less fit patients are being transplanted.44,45 Moreover, the
optimal cutoffs of “high” versus “low” would need to be
better defined and standardized before broader clinical
application of these results. Despite the need for further
research, our work supports the fact that subsequent stud-
ies, such as the BMT Clinical Trials Network study 1202,46
hold high promise for resulting in validated plasma-
derived biomarkers that could have prognostic and predic-
tive utility broadly applicable to patients undergoing
alloBMT, irrespective of the particular transplantation
platform employed.
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